ICPE All Access 2021
August 23-25, 2021 | Virtual
Gold Sponsor
August 2021
Carelon Research is a proud sponsor of ICPE All Access 2021! Our researchers will deliver poster and oral presentations, skills courses, and a workshop on a variety of trending topics such as COVID-19, oncology, and more.
View all Carelon Research presentations at https://icpemeeting.secure-platform.com/a/
SKILLS COURSES
Monday, August 16 | 8:00 AM – 12:00 PM ET
Using pharmacoepidemiology database resources to address drug safety research
Presentation on data validation approaches in pharmacoepidemiology
Daniel Beachler, PhD, MHS, Carelon Research
Workshop on database selection
Kevin Haynes, PharmD, MSCE, Carelon Research
SKILLS COURSES
Thursday, August 19 | 12:00 – 4:00 PM ET
Emerging methods in pragmatic trials: the AIRWISE study: study design features and lessons learned
Vincent Willey, PharmD, BCACP, Carelon Research
Carelon Research presentations
Carelon Research authors are indicated in bold.
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Poster
|
On-demand |
A new United States database for pharmacoepidemiology studies in type 2 diabetes mellitus: the IMEDS distributed database |
Huang TY1, Rodriguez-Watson C2, Wang T3, Calhoun S3, Marshall J1, Burk J1, Nam YH1, Mendelsohn AB1, Adgent M4, Jamal-Allial A5, Greenlee R6, Nair V7, Pawloski PA8, McMahill-Walraven CN9, Brown JS1 |
1Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, 2Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC, 3Merck & Co, Inc., Kenilworth, NJ, 4Vanderbilt University Medical Center, Nashville, TN, 5Carelon Research, Watertown, MA, 6Marshfield Clinical Research Institute, Marshfield, WI, 7Humana Healthcare Research, Inc., Louisville, KY, 8HealthPartners, Bloomington, MN, 9CVS Health Clinical Trial Services, Blue Bell, PA |
|
Poster |
On-demand |
The incidence rates of hepatobiliary diseases among non-alcoholic steatohepatitis patients stratified by fibrosis-4 (FIB-4) index for liver fibrosis |
Jamal-Allial A1 , Gallagher K1, Capozza T2, Du S1, Ness E2, Nguyen MH3, Patel YA4, Esposito DB1,5,6*, Titievsky L2 |
1Carelon Research, Watertown, MA, 2Intercept Pharmaceuticals, New York, NY, 3Duke University, Durham, NC, 4Stanford University, Stanford, CA, 5Boston University School of Public Health, Boston, MA, 6Ciconia, Inc., Westford, MA |
|
Poster |
On-demand |
Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a population with osteoarthritis |
Shinde M1, Rodriguez-Watson C2, Zhang TC1, Carrell DS3, Mendelsohn AB1, Nam YH1, Petronis KR4, McMahill-Walraven CN5, Jamal-Allial A6, Nair V7, Pawloski PA8, Hickman A9, Brown MT9, Francis J10, Hornbuckle K10, Brown JS1, Mo J4L2 |
1Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, 2Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC, 3Kaiser Permanente Washington Health Research Institute, Seattle, WA, 4Pfizer, New York, NY, 5CVS Health Clinical Trial Services (fka Healthagen), an affiliate of Aetna, Blue Bell, PA, 6Carelon Research, Watertown, MA, 7Humana Healthcare Research Inc, Louisville, KY, 8HealthPartners, Bloomington, MN, 9Pfizer, Groton, CT, 10Eli Lilly and Company, Indianapolis, IN |
|
Poster |
On-demand |
Factors associated with adherence to newly initiated JAK inhibitors in rheumatoid arthritis patients |
He X1, Mai X1, Beachler D1 |
1Carelon Research, Wilmington, DE |
|
Poster |
On-demand |
Trends in hydroxychloroquine drug utilization and safety in 2020 |
Hoffman SR1, Shambhu S1, Willey VJ1, Haynes K1 L2 |
1Carelon Research, Wilmington, DE |
|
Workshop Monday, August 23 |
Disease epidemiology/clinical course |
WS-15 | Real world data in the era of Covid-19: the devil in the details. An ISPE RWE task force/COVID-19 workgroup symposium |
Gabarro MS1, Teltsch DY2, Gokhale M3, Petraro P4, Rassen JA5, Lanes S6, Setoguchi S7, Prieto-Alhambra D8 |
1Bayer AG, Berlin, Germany, 2Apellis, Waltham, MA, 3Merck, West Point, PA, 4Boehringer Ingelheim, Ingelheim, Germany, 5Aetion, New York, NY, 6Carelon Research, Wilmington, DE, 7Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 8University of Oxford, Oxford, United Kingdom |
|
Oral Presentation Wednesday, August 25 |
Disease epidemiology/clinical course |
OP-7A | Impact of non-alcoholic steatohepatitis (NASH) case definition on population characteristics identified in a US claims database |
Gallagher K1, Esposito D1*, Jamal-Allial A1, Du S1, Nguyen M2, Ness E3, Capozza T3, Titievsky L3 |
1Carelon Research, Watertown, MA, 2Intercept Pharmaceuticals, New York, NY, 3Duke University, Durham, NC, 4Stanford University, Stanford, CA, 5Boston University School of Public Health, Boston, MA, 6Ciconia, Inc., Westford, MA |
|
Oral Presentation Wednesday, August 25 |
Safety end points application of pharmacoepidemiologic study designs for research across the cancer continuum |
OP-1C | Comparative safety of conjugated estrogens / bazedoxifene (CE/BZA) versus estrogen/progestin combination hormone therapy (EP): a multi-database cohort study |
Hoffman SR1, Governor SB1, Daniels KM1, Seals RM2, Ziyadeh NJ2, Wang F2, Dai D3, McMahill-Walraven CN3, Shuminski P3, Frajzyngier V4, Zhou X5, Shen R5, Fournakis N1, Beachler D1 |
1Carelon Research, Wilmington, DE, 2Optum, Boston, MA, 3CVS Health Clinical Trial Services (fka Healthagen), an affiliate of Aetna, Blue Bell, PA, 4Boehringer Ingelheim, Brooklyn, NY, 5Pfizer, New York, NY |
